The influence of thymosin injection combined with chemotherapy on the immune function and quality of life in patients with ovarian cancer
10.3760/cma.j.issn.1006-9801.2016.01.011
- VernacularTitle:胸腺肽注射液辅助化疗对卵巢癌患者免疫功能及生命质量的影响
- Author:
Yue CHENG
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Thymosin injection;
Drug therapy;
Immune function;
Quality of life
- From:
Cancer Research and Clinic
2016;28(1):48-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influence of thymosin injection combined with chemotherapy on the immune function and quality of life in patients with ovarian cancer. Methods A total of 206 patients with ovarian cancer were chosen and were divided into the control group (n = 103) and the observation group (n = 103) according to the random number table. The control group received chemotherapy. Based on the treatment of control group, the observation group was additionally treated with thymosin injection, the immune function and quality of life were analyzed and compared between two groups. Results The rates of effectivity and disease control were higher in the observation group than those in the control group [44.66 % (46/103) vs 30.10 % (31/103), 86.41 % (89/103) vs 66.99 % (69/103)], the differences were statistically significant (χ2 =3.942, 4.138, P = 0.022, 0.015), and number of cases of adverse reactions were lower in observation group than those in the control group (22 cases vs 35 cases, χ2= 3.601, P = 0.026), and the improvement rate of quality of life of patients were higher in the observation group than that in the control group [60.19 % (62/103) vs 40.78 % (42/103), χ2 = 3.974, P = 0.021]. After treatment, the expression levels of IgA, IgG, IgM and CD3, CD4, CD4/CD8, NK cells were significantly higher in the observation group than those in the control group, the difference was statistically significant (all P < 0.05). Conclusion Thymosin injection combined with chemotherapy is helpful to improve the immune function and the quality of life in patients with ovarian cancer, it is worthy of wider promotion and application.
